Please assess the completion status of the following clinical trial:

Trial Title: Human Anti-tumor Necrosis Factor (TNF) Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must be \>= 18 years of age~* meet Modified NY Criteria definition of ankylosing spondylitis (AS)~* have diagnosis of active AS based on protocol specified criteria~* inadequate response or intolerance to \>= 1 nonsteroidal antiinflammatory drug (NSAID)~* be able and willing to learn to self-administer subcutaneous (SC) injections~Exclusion Criteria:~* Active tuberculosis, listeriosis,or hepatitis B, or any history of hepatitis C~* History of demyelinating disease, multiple sclerosis, cancer, or lymphoproliferative disease~* Previous anti-tumor necrosis factor therapy~* Treatment with disease-modifying antirheumatic drugs (DMARDs - other than methotrexate, hydroxychloroquine, and sulfasalazine)~* Treatment with intra-articular corticosteroid joint injections within 4 weeks of study dosing~* Biologic or investigational therapy within 6 weeks of study dosing~* Treatment with intravenous (IV) antibiotics within 30 days of study dosing~* Treatment with oral antibiotics within 14 days of study dosing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adalimumab (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).